Michelle Doig

Michelle Doig

52 year
Finance
Health Technology
Consumer Services

Profile

Ms. Michelle Doig is an Independent Director at Bridgebio Oncology Therapeutics, Inc. /New/, a President & Director at Omega Alpha SPAC and a Partner & Head-Corporate Development at Omega Fund Management LLC.
She is on the Board of Directors at Bridgebio Oncology Therapeutics, Inc., Bridgebio Oncology Therapeutics, Inc. /New/, Artios Pharma Ltd., Omega Alpha SPAC and Nuvation Bio Operating Co., Inc. Ms. Doig was previously employed as a Director-Corporate Finance by Third Rock Ventures LLC, a Principal by Abingworth LLP, an Associate by Lehman Brothers, Inc., an Associate by J.P.
Morgan & Co., Inc. (Delaware), an Analyst by Morgan Stanley, and a Manager by Student Works Management Program.
She also served on the board at Nuvation Bio, Inc. She received her undergraduate degree from Richard Ivey School of Business.

Michelle Doig active positions

CompaniesPositionStart
OMEGA ALPHA SPAC Founder 01/11/2020
Private Equity Investor 01/01/2016
Director/Board Member -
Director/Board Member 01/07/2021

Former positions of Michelle Doig

CompaniesPositionEnd
NUVATION BIO INC. Director/Board Member 31/07/2021
Private Equity Investor 31/12/2016
Corporate Officer/Principal 01/11/2013
Corporate Officer/Principal 01/01/2002
Corporate Officer/Principal 01/03/2001
See the detail of Michelle Doig's experience

Training of Michelle Doig

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

76

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Finance

Finance

Finance

Finance

Finance

Consumer Services

Health Technology

Finance

Health Technology

Finance

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!